Arrowhead Pharmaceuticals has been granted a patent for RNAi agents targeting the AAT gene to treat diseases like chronic hepatitis and cirrhosis. The patent covers compositions and methods for delivering these agents to liver cells for effective treatment. GlobalData’s report on Arrowhead Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Arrowhead Pharmaceuticals, Targeted cancer therapy was a key innovation area identified from patents. Arrowhead Pharmaceuticals's grant share as of January 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
Rnai agents for treating diseases associated with aat deficiency
See Also:
A recently granted patent (Publication Number: US11884920B2) discloses an RNAi agent designed to inhibit the expression of the alpha-1 antitrypsin (AAT) gene. The RNAi agent consists of a sense strand and an antisense strand, with specific nucleotide sequences outlined in the claims. The patent details the composition of the RNAi agent, including the presence of targeting groups such as the asialoglycoprotein receptor ligand, N-acetylgalactosamine trimer, and various structures like (NAG25), (NAG26), (NAG27), among others. Additionally, the patent specifies the chemical structure of the RNAi agent, with modified nucleotides and phosphorothioate linkages playing a crucial role in its design.
Furthermore, the patent describes the formulation of a composition containing the RNAi agent and pharmaceutically acceptable excipients, suitable for subcutaneous injection. The composition aims to provide a targeted approach to inhibit the expression of the AAT gene, potentially offering therapeutic benefits in conditions associated with AAT deficiency. The detailed sequences and modifications of the RNAi agent outlined in the patent highlight the precision and specificity of the designed agent, emphasizing its potential in the field of genetic therapies. Overall, the patent sheds light on innovative strategies for gene regulation and opens up possibilities for the development of novel treatments targeting AAT-related disorders.
To know more about GlobalData’s detailed insights on Arrowhead Pharmaceuticals, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
